The data revealed precise, relevant interactions between these targets and highlighted the PI3K/AKT/NF-κB pathway as an essential target worthy of further investigation in the context of NAFLD treatment using ZXD. This evidence concerns the gene AKT1 and metabolic dysfunction-associated steatotic liver disease.